The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Me again.
Ignore the middle paragraph of my last post.The pictures in the article I read look like a generic stock photo of a glucose monitor.
Looking a volition diagnostics their science is at earlyish stage in relation to sepsis and like the paraytec analyser still doesn't look like a POCT suitable analyser
Demo123.
It's not "out there already",it is at the start year long trial and will run alongside and retrospective sepsis cases to compare its efficacy against existing protocols.
It does look more user friendly and seems to primarily be a sepsis only detection device,both would give it an advantage in a POCT setting.
The CX300 is being designed as multi channel analyser which can still have a place.
Demo, what company is that which has something out there now? I thought our gizmo was the only one on trial.
Worried now after seeing that post relating to someone's got there product out there already missed the boat comes to mind
Theres a mention of the sepsis trials on page 2 of The Sun. Let us hope Trev can capitalise on this exposure.
The CX300 has multiple services + Very accurate, plenty of room in the market also it has grate potential for lots of different testing ,not long now with this new tec .
Breakthrough in sepsis treatment as new blood test can rapidly identify the 'silent killer' 45 minute test on trial St Thomas hospital . London
Dear Trevor I hope you’ve seen this POCT for sepsis! Lest the boat sails without us!
https://uk.news.yahoo.com/blood-test-rapidly-identify-sepsis-125557082.html
Sunday Times, front page article today on Sepsis blood test research, may increase interest?
From one sale to Nottingham university to a paraytec one billion buyout is a tad optimistic.
Strange RNS after yesterday's release but hey-ho.
In my opinion Paraytec are too small to break into the marketplace and there is little need to wait for any significant sales on their part.
To establish an acute POCT setting for the CX3000 it will require some deep pockets with an established sales force in procurement contracting,there will be a need for aftersales/rental reagent+consumables,software and technical support and service requirements.The more global you go the bigger everything becomes.
One conundrum is that any prospective interested party is basically buying the IP of the technology,which has more than sepsis to its bow, but isn't/won't be required in a POCT setting.
So who buys it,for what reasons,and to where,to get full value and range from it?
I would love £1 dividend.
I like it £1 Billion = £18 per share divi - gla xxx
You’re absolutely correct, it does work and seeking global partners to take a point-of-care instrument to the market.
Also the Company has engaged an M&A specialist to market Paraytec in order to seek potential acquirers for the business, products and technology portfolio.
This bit I like = to seek potential acquirers for the business, products and technology portfolio.
It would be a sinn to sell Paraytec now before sale orders start, but if it is sold outright then it must be worth minimum one Billion , all major Pharma’s will be fighting for it, ALL MY OWN OPINION, GLA LTSH’s
This RNS looks to be confirmation that the device can indeed detect Sepsis in blood sample. The timing of this update was projected in a previous update regarding the device. Very positive I would suggest.
Why another update, could it be they already have a deal for Paraytec , it wouldn’t surprise me, they are very crafty.
Without going into detail, i remember we sold a crap business a couple of years ago, which gave a 40p dividend to each share and I think that business is now dead and buried.
Does anyone know of any similar business to Paraytec that have sold.
As a LTSH who is deeply under water, it would ease the frustration if a value could be put on a sale, i know this is an almost impossible ask, but there is no arm in asking. GLA LTH’s
Dire
TB talked of 70+ interested parties I paraytec in the covid days which materialised to nothing.
Paraytec could never market this effectively and am glad that selling is the idea going forward.
Phasefocus and Kirkstall both offer good products,but again progress is painfully slow.
Hi Castle. Dont you think it sounds like TB has had enough - first with face masks and now with the Sheffield lot without being too disrectful. Just hope to get a special divi for Paraytec
With a net asset value of 15.42p per share + sale of Paraytec or further development we have a lot of catching up to do!!
CASH flow is king , balance the books , sad decisions but correct to sell paraytec,,, when it sells it would be hard to put a value on it , anybody guess? I like organ on a chip too looks promising..
Castle
Sounds as though Paraytec is being sold too soon, just to keep the costs /wages of the company covered..
Hi. Thanks for your comment. This is all about commercialiition which has not happened with involvement of academics involved with our leaders projects over recent years and I guess TB is sick of it and some of us also have too many shares to have the same sentiment so dont get personal
“Doesn’t look too good…”
Reading comprehension clearly isn’t your strong point.
That’s just the sort of report long term investors were expecting. There’s quite a bit in there to be optimistic about.